Organicell Regenerative Medicine, Inc.
OCEL · OTC
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Revenue | $5 | $5 | $6 | $6 |
| % Growth | 1.4% | -29.8% | 16% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | $4 | $4 | $6 | $5 |
| % Margin | 81.7% | 88.9% | 88.4% | 90.2% |
| R&D Expenses | $0 | $0 | $1 | $1 |
| G&A Expenses | $9 | $11 | $15 | $18 |
| SG&A Expenses | $9 | $10 | $15 | $18 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $9 | $11 | $15 | $18 |
| Operating Income | -$5 | -$7 | -$9 | -$13 |
| % Margin | -115.1% | -148.5% | -136.2% | -227.7% |
| Other Income/Exp. Net | $1 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$5 | -$7 | -$9 | -$13 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$7 | -$9 | -$13 |
| % Margin | -101.8% | -153.3% | -137.9% | -229% |
| EPS | -0.74 | -0.99 | -1.57 | -2.42 |
| % Growth | 25.3% | 36.9% | 35.1% | – |
| EPS Diluted | -0.74 | -0.99 | -1.57 | -2.42 |
| Weighted Avg Shares Out | 6 | 7 | 6 | 5 |
| Weighted Avg Shares Out Dil | 6 | 7 | 6 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $1 | $0 |
| EBITDA | -$5 | -$6 | -$8 | -$13 |
| % Margin | -115.1% | -133.1% | -125.8% | -226.3% |